Coroflo is a technology company.
Coroflo has raised $3.0M across 1 funding round.
Coroflo has raised $3.0M in total across 1 funding round.
Coroflo has raised $3.0M in total across 1 funding round.
Coroflo's investors include Backed VC, Brand Capital International, Molten Ventures, Pareto Holdings, Albert Armengol, Felipe Navio, Juan Urdiales, Omid Ashtari.
Coroflo is a Dublin-based medtech company founded in 2016 that develops Coro, the world's first accurate breastfeeding monitor—a nipple shield with embedded flow sensors that tracks milk flow rates (ml/s), volumes (ml), and temperature in real-time via a connected app.[1][2][3] It serves new mothers, healthcare professionals, and breastfeeding research groups by addressing the critical problem of unreliable breastfeeding measurement, where traditional pre- and post-feed weigh-ins are inaccurate and stressful, often leading to anxiety over insufficient milk supply.[1][2][3] The company has raised $7.59M total, with its latest $3M unattributed round five months ago, signaling strong growth momentum in the connected breastfeeding wearables market, where it's positioned as a Challenger alongside leaders like Elvie, Willow, and Medela.[1][3]
Coroflo emerged from a personal challenge faced by co-founder Helen Barry, a doctor and Chief Research Officer, who struggled to monitor her preterm son's milk intake during breastfeeding due to inconsistent weigh-ins.[2] Her husband, Jamie Barry, an engineer with prior experience in flow monitoring technology, proposed adapting that expertise into a nipple shield sensor; their friend Rosanne joined as co-founder after witnessing similar issues among peers.[2] Incorporated in 2016 at Dublin City University's Alpha campus, the idea quickly gained traction through extensive lab testing, clinical hospital studies in Ireland, and collaborations with UCLA and the Lundquist Institute for breast milk research.[1][3]
Coroflo rides the FemTech wave, targeting women's health innovations amid rising demand for digital maternal care tools, with the connected breastfeeding market growing via smartphone-integrated wearables that support tracking and guidance.[1] Timing aligns with post-pandemic emphasis on home health monitoring and research into lactation dynamics, fueled by market forces like increasing preterm births, maternal anxiety, and gaps in traditional pediatrics.[2][3] It influences the ecosystem by enabling precise data for studies (e.g., UCLA partnerships) and challenging incumbents like Medela, potentially standardizing real-time breastfeeding metrics in healthcare.[1][3]
Coroflo's recent funding and research expansions signal scaling toward commercial launch and global adoption, likely expanding app features, hospital integrations, and FemTech partnerships amid trends like AI-driven health analytics and personalized maternal care.[1][3] Regulatory approvals and larger trials could amplify its influence, evolving from consumer gadget to essential research tool, ultimately empowering millions of mothers with data once unimaginable—transforming breastfeeding from guesswork to precision.
Coroflo has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $3.0M Seed | Backed VC, Brand Capital International, Molten Ventures, Pareto Holdings, Albert Armengol, Felipe Navio, Juan Urdiales, Omid Ashtari |